This is a Phase II clinical study to determine if Metformin can increase Prostate Specific
Antigen (PSA) doubling time for patients with Prostate Cancer who have failed primary
treatment with radiation, or surgical patients that are at high risk for recurrence based on
surgical pathology. Men with confirmed prostate cancer and rising serum PSA levels will
receive Metformin and will be monitored for PSA response and disease progression.